Study links heart surgery drug to death risk

An international study recently found that a widely-used drug in the prevention of excessive bleeding during heart surgery raises the risk of dying in the next five years afterward by nearly 50 percent. The researchers said that replacing the drug aprotinin sold by Bayer AG under the brand name Trasylol with other cheaper medications for a year would prevent 10,000 deaths worldwide over the next five years. Furthermore, the scientists found the same drug raised the risk of kidney failure, heart attacks, and strokes.

For the full article.

Lawyer Monthly - Legal Awards Winner
The National Trial Lawyers
Elder Care Matters Alliance
American Association for Justice
Fellow Litigation Counsel of America
Super Lawyers